106 results about "Peptide structure" patented technology

The invention belongs to the technical field of organic synthesis, and particularly discloses an ammonia aromatic alkene modified near-infrared BODIPY fluorescent probe as well as a preparation method and application thereof.The near-infrared BODIPY fluorescent probe is obtained by adopting 6-(dimethylamino) nicotinic aldehyde to directionally modify the alpha position of BODIPY and constructing an expanded conjugated system through Knoevenagel condensation. Wherein dimethylamino provides a strong electron donating effect, a molecular structure is twisted into a non-planar configuration due to steric hindrance of a pyridine ring, pi-pi accumulation is reduced, and an ACQ effect is inhibited. According to the structural modification strategy, significant red shift of absorption / emission wavelength is realized by expanding a molecular pi-conjugated skeleton, and meanwhile, the stability of the BODIPY core and the quantum yield are effectively enhanced. The probe molecule can specifically recognize the diphenylalanine dipeptide structural unit by utilizing the synergistic coordination effect of the 2-aminopyridine derivative and the BODIPY mother nucleus, so that the selective detection of the Alzheimer's disease biomarker Abeta42 is realized, and a novel optical detection tool is provided for the early molecular diagnosis and targeted therapy of AD (Alzheimer's disease).

The invention belongs to the technical field of skin care product raw materials, and discloses an oligopeptide compound, a preparation method thereof, a beautifying composition and application. The oligopeptide compound has a structural formula of # imgabs0. The oligopeptide compound provided by the invention contains peptide fragments of antioxidant amino acids such as tyrosine (Tyr), beta-alanine (beta-Ala), cysteine (Cys) and proline (Pro), and the amino acids can directly participate in removal of free radicals or form a stable peptide structure to enhance the antioxidant effect; therefore, the oligopeptide compound with anti-oxidation and physiological repair effects is obtained. Meanwhile, a mild Fmoc route is adopted in the preparation method, the condensation reaction time of each step is short, the production period is greatly shortened, raw materials are convenient to obtain, the process is stable, the quality is controllable, the product yield and purity are high, and large-scale production can be achieved.

The present invention relates to the technical field of diabetes, and in particular to a controlled-release diabetic wound healing promoting treatment method, comprising the following treatment experimental steps: step S1: preparation of Hst1@PNPs; step S2: Coomassie brilliant blue staining; step S3: scanning and transmission electron microscopy detection; in the present invention, a slow-release Hst1 treatment method is constructed by encapsulating Hst1 into platelet membrane vesicles derived from autologous blood. On the one hand, the PNPs encapsulate the linear Hst1 peptide structure to prevent it from being rapidly degraded by high proteases in diabetic wound exudate, thereby improving bioavailability. On the other hand, the PNPs can adsorb excess LPS in the wound exudate, and cooperate with Hst1 to achieve anti-inflammatory and anti-oxidative stress effects. Subsequent cell and animal experiments further confirmed that Hst1@PNPs have the effects of anti-inflammatory, scavenging ROS, promoting re-epithelialization, collagen deposition and angiogenesis, thereby promoting diabetic wound healing.

The invention discloses a yak bone collagen peptide for improving osteoporosis and preparation and application thereof, and relates to the field of biological medicine, the yak bone collagen peptide comprises collagen peptide with the molecular weight of 500-2000 Daltons, contains a glycine-proline-hydroxyproline tripeptide core structure, can promote osteoblast differentiation and inhibit osteoclast activity, and can be used for treating osteoporosis. The amino acid sequence of the collagen peptide is any one of the following sequences: glycine-proline-hydroxyproline-glycine-glutamic acid-arginine, and the amino acid sequence of the collagen peptide is any one of the following sequences: glycine-proline-hydroxyproline-glycine-glutamic acid-arginine; and the amino acid is glycine, proline, hydroxyproline, serine, leucine and alanine. The yak bone collagen peptide has a unique glycine-proline-hydroxyproline tripeptide structure, the molecular weight is controlled within the range of 500-2000 Daltons, the structure can promote osteoblast differentiation and inhibit osteoclast activity at the same time, and the problem that a traditional osteoporosis treatment medicine is single in function is solved.

Disclosed are polypeptides comprising two heterologous polypeptide domains, wherein the first polypeptide domain comprises a Cas protein and wherein the second polypeptide domain comprises a zinc finger protein 865 (ZNF865) or fragment thereof. Disclosed are polynucleotides capable of encoding a polypeptide comprising two heterologous polypeptide domains, wherein the first polypeptide domain comprises a Cas protein and wherein the second polypeptide domain comprises ZNF865 or fragment thereof. Disclosed are vectors comprising one or more of the polynucleotides. Disclosed are methods of using the disclosed polypeptides, polynucleotides and vectors.

The invention discloses a deep learning algorithm for predicting a monomer and compound structure of cyclic peptide and linear peptide containing non-standard amino acid. The deep learning algorithm specifically comprises the following steps: constructing a training data set containing head and tail cyclopeptide monomers and compounds, disulfide bond cyclopeptide monomers and compounds, and linear peptide monomers and compounds of non-standard amino acid; training and optimizing the peptide structure prediction model containing the basic protein knowledge; constructing a test data set of a linear peptide monomer containing non-standard amino acid, a linear peptide compound, a head-tail cyclopeptide monomer and a disulfide bond cyclopeptide monomer; and testing on the test data set by using the trained peptide structure prediction model. Compared with an existing peptide structure prediction model, high-precision structure prediction of monomers and compounds of cyclic peptide and linear peptide containing non-standard amino acid is proposed for the first time, structural information or pocket information of any target protein is not needed, and only one-dimensional sequences of the protein and side chain groups of the non-standard amino acid need to be input, so that the non-standard amino acid containing cyclic peptide and linear peptide is obtained. And the three-dimensional structure of the polypeptide can be accurately predicted.

The invention provides a hair care composition with oil control, hair loss prevention and repair effects and a preparation method of the hair care composition, and belongs to the technical field of hair care. The hair care composition comprises functional peptides such as myristoyl pentapeptide-4, palmitoyl tripeptide-1, acetyl tetrapeptide-3, hexapeptide-3, acetyl hexapeptide-8, palmitoyl tetrapeptide-7 and the like which are synergistically combined according to a specific proportion, and glycerin, water and a penetration enhancer are supplemented to form a basic system. By optimizing peptide structure modification, adding proportion and the steps of pH control, ultrasonic treatment and collaborative assembly in the preparation process, multi-path collaborative regulation and control of hair follicle activation, scalp inflammation inhibition and keratin synthesis enhancement are realized.

The invention belongs to the technical field of biological medicines, and particularly relates to an active peptide with a function of repairing neuroinflammation after spinal cord injury and a preparation method and application thereof. The invention firstly provides a recombinant active peptide. The structure of the recombinant active peptide at least comprises two groups of alpha spiral fragments; the amino acid sequence of the recombinant active peptide is as shown in SEQ ID NO. 2 or SEQ ID NO. 3. The bioactive peptide and the prepared nanofiber provided by the invention can effectively repair neuroinflammation after spinal cord injury, and have relatively high safety in a living body. And compared with the RK33A holoprotein, the RK33A holoprotein has a better effect.

The invention provides an antibacterial peptide and application thereof in resisting bacteria and / or enhancing the disease resistance of plants. Specifically, on one hand, the invention provides two antibacterial peptides which are novel functional antibacterial peptides ZJUAMP3 and ZJUAMP4, sequences of the novel functional antibacterial peptides ZJUAMP3 and ZJUAMP4 are respectively shown as SEQ ID NO: 1 and SEQ ID NO: 2, and the antibacterial peptides ZJUAMP3 and ZJUAMP4 both have broad-spectrum antibacterial activity, have good antibacterial activity on bacteria such as gram-negative bacteria, gram-positive bacteria and fungi, and are suitable for scenes needing sterilization or fungus and bacterium growth inhibition. Besides, the ZJUAMP4 can activate an MAPK signal channel in a plant body and induce the plant to generate systematic disease resistance, and is suitable for the fields of crop disease prevention and control and plant protection. The antibacterial peptide is simple in structure and easy to synthesize.

Provided herein are viral particles comprising a heterologous viral glycoprotein and a targeting moiety wherein the targeting moiety comprises a polypeptide comprising the formula T-S1 wherein T is a target binding domain and Si is a stem moiety. The stem portion may comprise a variant Fc domain. The stem portion may comprise a flexible polypeptide domain. The targeting moiety comprising the formula T-S1 may be incorporated into viral particles to help target such particles to specific cell types. Also provided herein are compositions comprising the viral particles, and methods of use thereof.

The invention relates to the field of biological information, and discloses a toxic protein library building method, device, equipment and medium, and the method comprises the following steps: obtaining a consensus peptide structure corresponding to a confirmed toxic protein sequence, and determining a toxic protein library on the basis of function expression characteristic data and fluctuation trend characteristic data of the consensus peptide structure; and constructing a target toxic protein core peptide set capable of covering the key functional domain of the confirmed toxic protein sequence. And performing function screening on the to-be-identified protein sequence on the functional feature domain by using the target toxic protein core peptide set to obtain an intermediate protein sequence which needs to be verified whether to conform to the toxic feature, performing toxicity screening on the intermediate protein sequence on the toxic feature domain, and determining the intermediate protein sequence conforming to the toxic feature as a target toxic protein sequence. And finally, constructing a toxic protein database by using the target toxic protein sequence. Therefore, through a two-layer screening mode combining function screening and toxicity screening, the toxic protein library building method which can discover new toxic proteins and detect low-abundance toxic proteins and is wide in coverage range is achieved.

The invention discloses a preparation method of a high-activity mitochondrial targeting MAPS polypeptide preparation, and relates to the technical field of biologication.The preparation method comprises the steps of S1, polypeptide design and synthesis, S2, thiol oriented cross-linking, S3, cutting and purification, S4, liposome assembly and S5, freeze-drying preparation molding.The preparation method has the advantages that by designing an amphipathic alpha-spiral polypeptide structure, the high-activity mitochondrial targeting MAPS polypeptide preparation is obtained; a stable helical conformation is spontaneously formed in a physiological environment by utilizing the alternative arrangement characteristic of hydrophobic and hydrophilic residues; the hydrophobic surface of the conformation can effectively interact with the mitochondrial membrane lipid bilayer, so that the transmembrane resistance is reduced; meanwhile, the hydrophilic surface is combined with the high negative membrane potential of the mitochondrial inner membrane through charge interaction to form a directional driving effect, so that the active transfer efficiency of the polypeptide under the mitochondrial membrane potential is remarkably improved; in addition, the integrated mitochondrial positioning signal further specifically recognizes the mitochondrial outer membrane transporter, the polypeptide is assisted to be accurately anchored to the targeting site, and non-specific diffusion is reduced.

A method and system for diagnosing a subject with respect to a nasopharyngeal carcinoma (NPC) disease state. Peptide structure data corresponding to a biological sample obtained from the subject is received. The peptide structure data is analyzed using a supervised machine learning model to generate a disease indicator that indicates whether biological sample evidences the NPC disease state based on at least 3 peptide structures selected from a group of peptide structures identified in Table 1A and / or 1B. The group of peptide structures in Table 1A and / or 1B comprises a group of peptide structures associated with the NPC disease state. The group of peptide structures is listed in Table 1A and / or 1B with respect to relative significance to the disease indicator. A diagnosis output is generated based on the disease indicator.

Disclosed are compositions and methods for treating a disease or disorder such as cancer in a subject in need thereof. In some embodiments, the methods include administering to the subject a vector that has a first nucleic acid sequence encoding a promoter operably linked to each of a second nucleic acid sequence encoding a therapeutic polypeptide, and a third nucleic acid sequence encoding a peptide domain that is stabilized when phosphorylated by kinase activity in a target cell and / or tissue. In some embodiments, the target cell and / or tissue can be a cell and / or tissue undergoing a stress response. In some embodiments, the target cell and / or tissue can be a cell and / or tissue in which a CK2 kinase is active. The kinase activity can be elevated extracellular regulated kinase (ERK) activity, p38 MAP kinase activity, and / or CK2 activity.

This invention discloses a therapeutic molecule, nanoparticles, and their preparation method for locating and stabilizing atherosclerotic plaques. The therapeutic molecule is synthesized based on cholanonic acid and copper peptide, and the nanoparticles are formed by the self-assembly of the therapeutic molecule. The preparation method involves aldehyde modification of both ends of cholanonic acid and coupling it with copper peptide via a Schiff base reaction to obtain a therapeutic molecule with both diagnostic and therapeutic functions. The copper peptide structure in the therapeutic molecule serves as the hydrophilic segment, and the cholanonic acid structure serves as the hydrophilic segment, allowing it to further self-assemble into nanoparticles in water. These nanoparticles exhibit acid responsiveness and can disintegrate in the slightly acidic environment of atherosclerotic sites. The released copper peptide can stabilize plaques by promoting collagen secretion and inhibiting matrix metalloproteinase expression. Simultaneously, the X-ray imaging characteristics of cholanonic acid can be used to locate and diagnose the distribution of plaques, thus achieving integrated stabilization and localization of atherosclerotic plaques.

This invention relates to the field of bioinformatics processing and discloses a method and system for mining the structure-activity relationship (SMR) of porcine neurotrophic peptides based on sequence features. The method includes constructing an original sample index table and fusing multi-source production data, extracting peptide sequence features to generate a sequence feature matrix, constructing a sequence-process joint graph containing peptide nodes and process state nodes, training a structure-activity relationship graph neural network to mine SMR relationships, and deriving a process control decision table based on a process response sample set generated by the network, thereby achieving online optimization of the porcine neurotrophic peptide preparation process. This invention solves the problem of SMR mining caused by the separation of process parameters, sequence information, and activity data, achieving accurate characterization of the synergistic effect of sequence and process and reverse optimization of process parameters, thus improving the targeted enrichment efficiency and bioactivity retention level of target neurotrophic peptides.

Disclosed are polypeptides comprising two heterologous polypeptide domains, wherein the first polypeptide domain comprises a Cas protein and wherein the second polypeptide domain comprises a zinc finger protein 865 (ZNF865) or fragment thereof. Disclosed are polynucleotides capable of encoding a polypeptide comprising two heterologous polypeptide domains, wherein the first polypeptide domain comprises a Cas protein and wherein the second polypeptide domain comprises ZNF865 or fragment thereof. Disclosed are vectors comprising one or more of the polynucleotides. Disclosed are methods of using the disclosed polypeptides, polynucleotides and vectors.

The present invention provides novel uricase conjugates comprising a first domain and a second domain. The first domain comprises a uricase polypeptide and the second domain is an unstructured random coil polypeptide domain comprising at least about 100 amino acids. The invention also provides methods of using the uricase conjugates of the invention, e.g., for the treatment of tumor lysis syndrome and / or gout.

Provided are multivalent D-peptide compounds that specifically bind to a protein of interest. The multivalent D-peptide compounds may include two or more different variant D-peptide domains linked via a linking component. The D-peptide compounds may include a plurality of different domains that specifically bind to different binding sites on a protein of interest to provide high affinity binding to and potent activity against the protein of interest. Also provided are D-peptide variant GA domain polypeptides and D-peptide variant Z domain polypeptides having a Specific Determining Motif (SDM) for specific binding to a protein of interest, such as VEGF-A or PD-1. In some embodiments in which the protein of interest is a homodimeric protein of interest (e.g., VEGF-A, PD-1), the D-peptide compounds may be similarly dimeric and include dimers of multivalent (e.g., divalent) D-peptide compounds. Methods of using the compounds are provided, including methods of treating a disease or condition associated with a protein of interest in a subject.

This invention provides modified antimicrobial peptides, belonging to the field of antimicrobial peptide technology. The modified antimicrobial peptides include at least one of a first, second, third, fourth, fifth, and sixth antimicrobial peptide; the amino acid sequences of the first, second, third, fourth, fifth, and sixth antimicrobial peptides are shown sequentially as SEQ ID NO.1 to SEQ ID NO.6. Based on prevotellin-2, the modified antimicrobial peptides were obtained by reducing negatively charged amino acids, increasing positively charged amino acids, introducing hydrophobic amino acids, adjusting or deleting amino acid sequences, and optimizing the peptide structure. In vitro minimum inhibitory concentration (MIC) determination showed that, compared with the initial peptide, the modified antimicrobial peptides exhibited significantly enhanced antimicrobial activity against bacteria and fungi, and also showed significant bactericidal activity against clinically resistant bacteria.

The present invention discloses a biphenyl bridged cyclic peptide compound and a preparation method and application thereof. Phenylalanine or p-hydroxyphenylalanine, which is easily available, is used as the initial raw material. After methylation, protective groups are installed on the carboxyl group and the amino group to obtain two intermediate compounds. The installed 2-methoxyiminoacyl group (methoxyoxime acyl group) is used to guide the transition metal to activate the carbon-hydrogen bond, and the two intermediates are connected in the form of a carbon-carbon bond. Finally, after hydrogenation reduction, lactamization ring closure is performed to obtain the biphenyl bridged cyclic peptide compound. The present invention utilizes the bidentate ligand guiding function of the 2-methoxyiminoacyl group and the instantaneous guiding function of norbornene (NBE) to guide the transition metal to activate the sp at the meta position of the aromatic ring. 2 The carbon-hydrogen bond is formed, and then an arylation reaction occurs to construct a biphenyl structure. The 2-methoxyiminoacyl group is then hydrogenated to form a dipeptide structure, and finally the biphenyl cyclic peptide is constructed by lactamization. The entire route is simple and efficient, and is expected to be further promoted and applied.

Provided is a compound that includes a peptide structure represented by Formula (p1) or (p2). Also provided is a method for producing droplets using the compound. Xa is an amino acid residue having a hydrophilic side chain; Xb is an amino acid residue having a side chain represented by Formula (b1); Xc and Xd are each independently an amino acid residue or a glycine residue having a hydrophobic side chain; and n is an integer of 1 to 3. Ar1 is an aryl group or heteroaryl group which may have a substituent; and Ar2 is an arylene group or a heteroarylene group which may have a substituent.

This invention discloses a method for screening pancreatic lipase inhibitory peptides based on machine learning, relating to the fields of bioinformatics and food science. The method includes the following steps: dataset construction and three-dimensional peptide structure characterization, statistical-based feature screening, outlier removal based on a dual-model consensus mechanism, feature recursive elimination and physicochemical significance optimization, data augmentation based on Gaussian noise injection, and final prediction model construction. This invention effectively solves the problems of insufficient feature representation, high noise interference, and weak model generalization ability in existing screening methods through multi-dimensional feature characterization, rigorous outlier cleaning, and data augmentation strategies for small samples. It can quickly and accurately screen highly active pancreatic lipase inhibitory peptides from massive peptide sequences, providing an efficient computational tool for the development of functional foods and lipid-lowering drugs.

The invention belongs to the field of nucleic acid editing, and particularly relates to the technical field of regular clustering interval short palindromic repeat (CRISPR). Specifically, the invention provides the application of the chromosome regulating peptide structural domain in improving the Cas protein editing efficiency, and the chromosome regulating peptide structural domain has a wide application prospect.

This disclosure provides peptides which have an affinity for the focal adhesion targeting (FAT) domain of focal adhesion kinase (FAK). In particular, the peptides are modified and derived from the sequence of the LD2 alpha helical domain of paxillin (e.g., LD2 peptides), the LD4 domain of paxillin (e.g., LD4 peptides), and CD8 peptides. These peptides are capable of blocking an interaction between paxillin and FAK, thereby inhibiting FAK activity related to FAK-paxillin interaction. The invention further provides uses for such peptides as therapeutics for the treatment of cancer and other diseases characterized with FAK activity and / or expression (e.g., fibrosis).

The present disclosure provides a method for biocatalytic production of a polycyclic peptide comprising providing a peptide sequence containing a recognition motif for a radical S-adenosylmethionine metallocnzyme (SAM enzyme), exposing the peptide sequence to an enzymatic reaction including catalysis under standard enzymatic reaction conditions with the radical SAM enzyme, and generating a further cyclized peptide by modifying a product of the enzymatic reaction chemically and / or via enzymes. The radical SAM enzyme catalysis generates macrocyclic modifications using unactivated carbon centers. The product of the enzymatic reaction may be modified using haloalkane- or haloacetyl-containing compounds, macrocyclases, or additional radical SAM enzymes. The peptide sequence may be altered at permissive sites to generate libraries of polycyclic peptide structures. The enzymatic reaction may occur at ambient temperature and pH under buffered aqueous conditions.

Embodiments disclosed herein generally relate to technologies for evaluating a biological sample obtained from a subject with respect to a sepsis state or coronavirus disease (COVID). Some methods relating to the technologies can include receiving peptide structure data corresponding to the biological sample obtained from the subject, identifying a peptide structure profile for the biological sample using the peptide structure data, and computing a disease indicator using the peptide structure profile and a model. The disease indicator can indicate whether the biological sample is positive for the sepsis state. The disease indicator can indicate whether the biological sample is positive for COVID. The peptide structure profile can comprise quantification data for a set of peptide structures associated with the sepsis state. The peptide structure profile can include peptides that are glycosylated, aglycosylated, or both. An additional step in the method can comprise generating at least one of a diagnosis output or a treatment output based on the disease indicator.

The invention provides a peptide antibacterial compound as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a peptide compound zhenxinmyxin as shown in a formula I. The peptide compound has good structural characteristics, the antibacterial effect on staphylococcus aureus can be remarkably improved, the minimum inhibitory concentration on staphylococcus aureus ATCC 25923 and USA300 is 4 [mu] g / mL, and the peptide compound can be used for preparing drugs for resisting gram-positive bacterial infection. The peptide compound is a novel peptide structure compound extracted from fermentation liquor of streptomyces albidoflavus NX-12, raw materials are easy to obtain, the preparation method is simple and convenient, and the peptide compound is suitable for large-scale popularization and application.

Peptide structure particle with signal transmission, characterized in that it comprises a particle body which represents a spherical whole, wherein the particle body comprises, from the outside inwards, a protective membrane, a spherical capsule and a small peptide; The small peptide enhances the secretory capacity of the signal peptide, and its amino acid sequence is represented in the following general formula: M(αXβYγ / αYβXγ) η ; where X represents an acidic amino acid; α stands for 0-2 neutral amino acids; β stands for 0-2 neutral amino acids; γ represents 1-10 neutral amino acids; η 1-3 is; where “ / ” in the general formula means “or”.

The present invention relates to a peptide structure specifically binding to carbonic anhydrase IX (CAIX), and a use thereof. The CAIX-binding peptide ligand of the present invention contains D-amino acids, and thus has high binding specificity to CAIX while being stable in the body, and a cyclic CAIX-binding peptide structure comprising same can bind to CAIX with high affinity in the body, and thus is effective in the diagnosis, prevention, suppression or treatment of diseases mediated by CAIX.